Dipath Joins Astellas and Ecosystem Partners to Explore AI-Powered Digital Pathology for Precision Gastric Cancer Diagnosis
Dipath
AI-Assisted Diagnostic Tool Developer
On June 26, 2026, Dipath and partners including Astellas China jointly launchedAI Empowers a New Chapter in Precision Diagnosis of Gastric CancerAll parties will leverage their respective strengths in innovative drugs, digital pathology, AI-assisted diagnosis, and the development of pathological diagnostic systems to address the key biomarker testing needs in the precise diagnosis and treatment of gastric cancer. Together, they will explore practical pathways for the application of AI technology in the standardization, intelligentization, and clinical implementation of CLDN18.2 pathological testing.
This collaboration not only marks a significant milestone in Dipath’s continued dedication to the field of AI pathology, but also reflects the deeper integration of digital pathology technology with the concept of precision therapy. In the future, Dipath will leverage its self-developed AI algorithms and extensive experience in digital pathology platform construction to help improve the efficiency of pathological testing, consistency in interpretation, and standardization of diagnosis, thereby providing more reliable diagnostic support for the precision treatment of gastric cancer patients.
Gastric Cancer Enters the Era of Precision Diagnosis and Treatment, Highlighting the Growing Need for Standardized Pathological Testing
Gastric cancer is one of the most common malignant tumors of the digestive tract in China. With the continuous advancement of precision medicine, detection and treatment strategies targeting different molecular biomarkers are driving a shift in the diagnosis and treatment paradigm for gastric cancer—from traditional experience-based therapy to precise stratified treatment. Among these, CLDN18.2, a biomarker closely associated with gastric cancer therapy that has garnered significant attention in recent years, holds substantial importance in guiding treatment decisions based on its pathological test results.
However, in real-world clinical practice, CLDN18.2 immunohistochemistry testing continues to face multiple influencing factors, including sample quality, staining protocols, interpretation criteria, and variations in physician experience. Enhancing the consistency, reproducibility, and interpretability of results across different laboratories and testing scenarios has become a critical step in promoting the standardized implementation of related precision therapies.
As a critical basis for tumor diagnosis, pathological diagnosis plays a key role in the "front-end gatekeeping" of the precision treatment chain. In the face of the increasingly refined development trend of multi-target parallel testing and clinical medication decision-making, the pathological diagnosis system also needs to be continuously upgraded with the help of digital and intelligent technologies to better support clinical diagnosis and treatment needs.
Dipath AI Pathology Capabilities Continue to Deepen, DeepPathAI Helps Build an Efficient, Precise, and Reproducible Auxiliary Diagnostic System
Dipath has long been dedicated toIn the “AI + Pathology” domain, focusing on the daily workflows of pathologists, we continuously advance capabilities in artificial intelligence algorithms, digital pathology platforms, remote consultation, pathology information management, and cloud storage, striving to provide healthcare institutions with comprehensive, fully digital AI-powered pathology solutions. Building on this foundation, Dipath further leverages its independently developed large model, DeepPathAI, to elevate AI technology from single-point auxiliary interpretation tools to an integrated intelligent platform encompassing pathological diagnosis, drug development, companion diagnostics, and precision cancer diagnosis and treatment.
In the field of oncology diagnosis and treatment, Dipath leverages its self-developed AI algorithms and the image recognition, semantic understanding, and multimodal analysis capabilities of the DeepPathAI large model to perform intelligent identification and quantitative analysis of cellular morphology, tissue architecture, staining expression, and spatial distribution features. This assists physicians in improving interpretation efficiency and result consistency. For biomarker detection scenarios such as CLDN18.2, AI technology is poised to play a significant role in positive cell identification, expression intensity assessment, regional analysis, result quantification, and automated report generation. This helps pathologists achieve more efficient, stable, and reproducible interpretations in accordance with standardized guidelines.
More importantly, the large-model capabilities represented by DeepPathAI provide a new technological foundation for the further integration of AI technology into drug development and precision cancer diagnosis and treatment. On the drug development front, large models can help researchers gain a deeper understanding of tissue morphology, target expression characteristics, and potential drug response patterns, thereby supporting target research, patient stratification, clinical trial design, efficacy evaluation, and companion diagnostic development. In terms of clinical application, these models can assist in constructing more standardized, quantifiable, and interpretable biomarker assessment workflows, enabling clinicians to make higher-quality judgments regarding patient suitability for corresponding precision therapies.
The strategic launch of this collaboration with partners such as Astellas Pharma represents a significant initiative by Dipath to integrate the capabilities of its DeepPathAI large language model and its accumulated expertise in AI-powered pathology with the real-world clinical needs for precise diagnosis and treatment of gastric cancer. Through multi-party synergy, Dipath will further explore the application value of AI-assisted pathological diagnosis in CLDN18.2 testing, driving the evolution of pathological testing from an experience-driven approach to a more standardized, intelligent, and quantifiable stage. This effort also provides broader practical pathways for the deep integration of AI technology into new drug development, companion diagnostics, and precision cancer therapy.
Multi-party Collaboration: Co-building a New Ecosystem of Digital Pathology Empowering Precision Diagnosis and Treatment
High-quality development of precision diagnosis and treatment relies on the collaborative participation of innovative pharmaceutical companies, AI pathology enterprises, pathology diagnostic companies, and clinical experts. Astellas continues to advance innovative practices in the field of precision treatment for gastric cancer, while domestic AI pathology and pathology diagnostic companies such as Dipath have accumulated extensive expertise in digital pathology, AI-assisted interpretation, and the construction of pathology diagnostic systems.
This strategic collaboration, initiated with CLDN18.2 testing as the entry point, focuses on exploring key aspects of precision diagnosis and treatment for gastric cancer. It will help promote the establishment of standardized pathological testing processes, improve the efficiency and consistency of biomarker interpretation, and provide a more robust diagnostic foundation for precision therapy.
Yang Lin, Founder and Chairman of Dipath, stated：“Dipath has always been committed to deeply integrating AI algorithms with pathological diagnosis, creating efficient and precise auxiliary diagnostic solutions. While supporting the innovative development of pathology as a discipline, it leverages its original large model, DeepPathAI, to fully assist in the entire process of new drug development and companion diagnostics. This strategic launch with Astellas represents an important practice that organically combines ‘Chinese wisdom’ embodied by the large model with ‘global innovation,’ injecting new momentum into the standardization and intelligent upgrading of gastric cancer CLDN18.2 pathological companion diagnostics.”
Wang Kai, Head of the Digestive Oncology Business Unit at Astellas, stated：“Astellas is consistently committed to translating scientific advancements into patient value. In the current era, where gastric cancer management is entering an age of precision diagnosis and treatment, the timely and accurate identification of CLDN18.2-positive patients represents the critical first step in bringing the benefits of precision therapy to clinical practice. We aim to leverage artificial intelligence technology to continuously enhance the standardization of pathological testing. We are pleased to collaborate with three leading AI pathology companies to advance the standardization of precision diagnosis and treatment for gastric cancer, thereby enabling more Chinese patients to benefit from these innovations.”
Dishant Kalra, Global Brand Marketing and Strategic Precision Medicine at Astellas：“At Astellas, driving the synergistic advancement of precision diagnostics and therapeutics embodies our commitment to pioneering scientific discoveries and improving patient outcomes. China has demonstrated encouraging innovative vitality in the fields of digital pathology and artificial intelligence. We look forward to leveraging today’s launch as a new starting point to integrate the cutting-edge capabilities of Chinese pathological AI enterprises—such as algorithms, models, and deep learning—with the enhancement of global diagnostic standards for gastric cancer biomarkers, thereby accelerating the translation of innovative achievements to benefit patients worldwide.”
Unceasing Progress: Jointly Building a New Paradigm for Precision Diagnosis and Treatment of Gastric Cancer
In the future, Dipath will continue to uphold its development philosophy of “empowering pathology with AI and serving clinical practice through innovation.” By collaborating with partners across the industry chain, Dipath is committed to driving the deep integration of digital pathology and precision diagnosis and treatment. Through technological innovation and co-development of clinical scenarios, Dipath aims to provide pathologists with more efficient auxiliary tools, help healthcare institutions build more comprehensive digital pathology capabilities, and contribute to ensuring that more gastric cancer patients receive standardized, precise, and accessible diagnostic and therapeutic services.
About Dipath
HangZhou Dipath Technology Co., Ltd. has always been committed to deep cultivationAI-Driven Pathology Business Direction. By leveraging fully self-developed AI algorithms, we create multi-module AI-assisted diagnostic tools and independently developed large pathology models. Building on this foundation, we offer a comprehensive suite of services including cloud storage, pathology information management, and remote consultations, providing all-around support to pathologists. We are committed to delivering end-to-end digital AI pathology solutions for industry professionals.
About Astellas
Astellas is a global life sciences company dedicated to translating innovative science into value for patients. We provide transformative therapies in the disease areas of oncology, ophthalmology, urology, immunology, and women’s health. Through our research and development programs, we are pioneering novel medical solutions for diseases with high unmet medical needs.
For more information, please visit:www.astellas.com
Founded in 2017, Dipath has dedicated two decades to the field of AI-powered digital pathology. Upholding its mission to “illuminate pathology with intelligence and make precision medicine accessible,” the company is a leading provider of digital and intelligent pathology solutions in China. It has received over 200 honors, including recognition as a National High-Tech Enterprise, a Zhejiang Province Specialized, Refined, Differential, and Innovative (SRDI) Small and Medium-sized Enterprise, a Hangzhou Quasi-Unicorn, and a Zhejiang Science and Technology New Little Dragon. Since being classified as an enterprise above designated size in 2023, Dipath has maintained an annual revenue growth rate exceeding 70%, demonstrating strong momentum in its development.
On January 6, 2026, Professor Yang Lin, founder of the company and principal investigator of the Artificial Intelligence and Biomedical Imaging Laboratory at the School of Engineering, Westlake University, donated equity to Westlake University on behalf of the enterprise. This donation aims to deepen industry-academia-research-medical collaboration and promote high-quality development in the fields of medical-engineering interdisciplinary innovation and the digital-intelligent pathology industry.
World-Class R&D Strength
Full-Stack Independent Innovation
Full-Scenario Product Matrix
Large-Scale Clinical Implementation
Dipath · Global Talent Recruitment
HR Email: hr@dipath.cn
Westlake University Yang Lin Lab · PhD Recruitment
Submission Email:yanglinlab@westlake.edu.cn